Tuğba Başoğlu, Associate professor at Memorial Healthcare Group Göztepe Onkoloji Merkezi, shared a post on X:
“FDA Approval: A New Standard for Platinum-Resistant Ovarian Cancer!
The KEYNOTE-B96 trial has paved the way for a new treatment era. FDA has officially approved Pembrolizumab + Paclitaxel (+/- Bevacizumab) for patients with platinum-resistant ovarian cancer.
Key Highlights:
- Population: PD-L1 positive (CPS \geq 1) PROC patients.
- Clinical Benefit: Median OS reached 18.2 months vs. 14.0 months with chemotherapy (+4.2 months benefit)”
Other articles featuring Tuğba Başoğlu on OncoDaily.
